{"id":36285,"date":"2026-03-06T10:10:33","date_gmt":"2026-03-06T16:10:33","guid":{"rendered":"https:\/\/brakkeconsulting.com\/?p=36285"},"modified":"2026-03-06T10:10:33","modified_gmt":"2026-03-06T16:10:33","slug":"brakke-viewpoint-march-6-2026","status":"publish","type":"post","link":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-march-6-2026\/","title":{"rendered":"Mirante de Brakke 6 de mar\u00e7o de 2026"},"content":{"rendered":"<p>Foi um prazer para mim estar esta semana em Londres, junto com meus colegas da Brakke e muitos l\u00edderes globais da ind\u00fastria de sa\u00fade animal, para a Confer\u00eancia de Tecnologia e Inova\u00e7\u00e3o em Sa\u00fade e Nutri\u00e7\u00e3o Animal da Kisaco.<\/p>\n<p>A qualidade e a quantidade das apresenta\u00e7\u00f5es e conversas destacaram a for\u00e7a da ind\u00fastria de sa\u00fade animal e suas muitas oportunidades de inova\u00e7\u00e3o futuras.<\/p>\n<p>Uma apresenta\u00e7\u00e3o particularmente interessante foi a conversa mediada por Kristin Peck, CEO da Zoetis, e pelo Dr. Timothy Shell, Diretor do Centro de Medicina Veterin\u00e1ria (CVM) da FDA. O Dr. Shell compartilhou sua vis\u00e3o para a reforma do processo de aprova\u00e7\u00e3o de sa\u00fade animal do CVM, observando que as intera\u00e7\u00f5es com a FDA desempenhar\u00e3o um papel fundamental na defini\u00e7\u00e3o de como as inova\u00e7\u00f5es futuras chegar\u00e3o ao mercado.<\/p>\n<p>Ele mencionou diversas mudan\u00e7as propostas, alertando que estas n\u00e3o s\u00e3o orienta\u00e7\u00f5es formais e provavelmente levar\u00e3o de 3 a 5 anos para serem implementadas:<\/p>\n<ul>\n<li>Reduzir o tempo m\u00e9dio de aprova\u00e7\u00e3o de 10 anos para 5 anos.<\/li>\n<li>Triplicar as aprova\u00e7\u00f5es do MUMS de 2 para 6 por ano, com um programa de vouchers para revis\u00e3o acelerada.<\/li>\n<li>Prorroga\u00e7\u00e3o da aprova\u00e7\u00e3o condicional de 5 para 7 anos para doen\u00e7as cr\u00f4nicas e inclus\u00e3o da se\u00e7\u00e3o CMC.<\/li>\n<li>Atualiza\u00e7\u00e3o do programa de taxas de usu\u00e1rio para permitir avalia\u00e7\u00f5es mais curtas com taxas aplic\u00e1veis.<\/li>\n<li>Regulamenta\u00e7\u00f5es sobre res\u00edduos e toxicologia em evolu\u00e7\u00e3o<\/li>\n<li>Aproveitar os dados e as aprova\u00e7\u00f5es de ag\u00eancias estrangeiras, ao mesmo tempo que se resolvem as lacunas regulamentares dentro dos prazos estabelecidos.<\/li>\n<li>Utilizando IA para acelerar processos administrativos<\/li>\n<\/ul>\n<p>Para concluir, o Dr. Shell afirmou que o CVM est\u00e1 em constante evolu\u00e7\u00e3o e incentivou as empresas a nunca interromperem ou adiarem projetos sem antes consultar a ag\u00eancia. Essa colabora\u00e7\u00e3o apoiar\u00e1 a introdu\u00e7\u00e3o oportuna de valiosos produtos de sa\u00fade animal para animais de estima\u00e7\u00e3o e de produ\u00e7\u00e3o.<\/p>\n<p><em>Chuck Johnson, DVM, MBA<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>It was my pleasure this week to join my Brakke colleagues and many global animal health industry leaders in London for Kisaco\u2019s Animal Health &amp; Nutrition Technology and Innovation Conference. The quality and quantity of presentations and conversations highlighted the strength of the animal health industry and its many innovation opportunities ahead. A particularly refreshing presentation was a conversation facilitated by Kristin Peck, CEO of Zoetis, and Dr. Timothy Shell, Director of the FDA\u2019s Center for Veterinary Medicine (CVM). Dr. Shell shared his vision for reforming the CVM\u2019s animal health approval process, noting that FDA interactions will play a key role in determining how future innovations reach the market. He touched on several proposed changes\u2014cautioning these are not formal guidance and likely require 3\u20135 years to implement: Reducing average approval time from 10 years to 5 years Tripling MUMS approvals from 2 to 6 per year, with a voucher program for expedited review Extending conditional approval from 5 to 7 years for chronic diseases and including the CMC section Updating the user fee program to enable shorter reviews with applicable fees Evolving residue and toxicology regulations Leveraging\u00a0foreign agency data and approvals, while addressing regulatory gaps within set timelines Utilizing AI to accelerate administrative processes In closing, Dr. Shell stated that the CVM is evolving and encouraged companies never to pause<\/p>\n<div class=\"view-full-post\"><a href=\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-march-6-2026\/\" class=\"view-full-post-btn\">Ver postagem completa<\/a><\/div>\n<p>;<\/p>","protected":false},"author":19,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[43],"tags":[],"class_list":["post-36285","post","type-post","status-publish","format-standard","hentry","category-viewpoints"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>News from Brakke Consulting<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-march-6-2026\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News from Brakke Consulting\" \/>\n<meta property=\"og:description\" content=\"It was my pleasure this week to join my Brakke colleagues and many global animal health industry leaders in London for Kisaco\u2019s Animal Health &amp; Nutrition Technology and Innovation Conference. The quality and quantity of presentations and conversations highlighted the strength of the animal health industry and its many innovation opportunities ahead. A particularly refreshing presentation was a conversation facilitated by Kristin Peck, CEO of Zoetis, and Dr. Timothy Shell, Director of the FDA\u2019s Center for Veterinary Medicine (CVM). Dr. Shell shared his vision for reforming the CVM\u2019s animal health approval process, noting that FDA interactions will play a key role in determining how future innovations reach the market. He touched on several proposed changes\u2014cautioning these are not formal guidance and likely require 3\u20135 years to implement: Reducing average approval time from 10 years to 5 years Tripling MUMS approvals from 2 to 6 per year, with a voucher program for expedited review Extending conditional approval from 5 to 7 years for chronic diseases and including the CMC section Updating the user fee program to enable shorter reviews with applicable fees Evolving residue and toxicology regulations Leveraging\u00a0foreign agency data and approvals, while addressing regulatory gaps within set timelines Utilizing AI to accelerate administrative processes In closing, Dr. Shell stated that the CVM is evolving and encouraged companies never to pauseView Full Post;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-march-6-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Brakke Consulting Website\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-06T16:10:33+00:00\" \/>\n<meta name=\"author\" content=\"Amanda McDavid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Amanda McDavid\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-march-6-2026\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-march-6-2026\/\"},\"author\":{\"name\":\"Amanda McDavid\",\"@id\":\"https:\/\/brakkeconsulting.com\/pt\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\"},\"headline\":\"Brakke Viewpoint March 6, 2026\",\"datePublished\":\"2026-03-06T16:10:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-march-6-2026\/\"},\"wordCount\":249,\"articleSection\":[\"Viewpoints\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-march-6-2026\/\",\"url\":\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-march-6-2026\/\",\"name\":\"News from Brakke Consulting\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/pt\/#website\"},\"datePublished\":\"2026-03-06T16:10:33+00:00\",\"author\":{\"@id\":\"https:\/\/brakkeconsulting.com\/pt\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\"},\"breadcrumb\":{\"@id\":\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-march-6-2026\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-march-6-2026\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-march-6-2026\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/brakkeconsulting.com\/pt\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brakke Viewpoint March 6, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/brakkeconsulting.com\/pt\/#website\",\"url\":\"https:\/\/brakkeconsulting.com\/pt\/\",\"name\":\"Brakke Consulting Website\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/brakkeconsulting.com\/pt\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/brakkeconsulting.com\/pt\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\",\"name\":\"Amanda McDavid\",\"url\":\"https:\/\/brakkeconsulting.com\/pt\/author\/amanda\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Not\u00edcias da Brakke Consulting","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-march-6-2026\/","og_locale":"pt_PT","og_type":"article","og_title":"News from Brakke Consulting","og_description":"It was my pleasure this week to join my Brakke colleagues and many global animal health industry leaders in London for Kisaco\u2019s Animal Health &amp; Nutrition Technology and Innovation Conference. The quality and quantity of presentations and conversations highlighted the strength of the animal health industry and its many innovation opportunities ahead. A particularly refreshing presentation was a conversation facilitated by Kristin Peck, CEO of Zoetis, and Dr. Timothy Shell, Director of the FDA\u2019s Center for Veterinary Medicine (CVM). Dr. Shell shared his vision for reforming the CVM\u2019s animal health approval process, noting that FDA interactions will play a key role in determining how future innovations reach the market. He touched on several proposed changes\u2014cautioning these are not formal guidance and likely require 3\u20135 years to implement: Reducing average approval time from 10 years to 5 years Tripling MUMS approvals from 2 to 6 per year, with a voucher program for expedited review Extending conditional approval from 5 to 7 years for chronic diseases and including the CMC section Updating the user fee program to enable shorter reviews with applicable fees Evolving residue and toxicology regulations Leveraging\u00a0foreign agency data and approvals, while addressing regulatory gaps within set timelines Utilizing AI to accelerate administrative processes In closing, Dr. Shell stated that the CVM is evolving and encouraged companies never to pauseView Full Post;","og_url":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-march-6-2026\/","og_site_name":"Brakke Consulting Website","article_published_time":"2026-03-06T16:10:33+00:00","author":"Amanda McDavid","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Amanda McDavid","Tempo estimado de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-march-6-2026\/#article","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-march-6-2026\/"},"author":{"name":"Amanda McDavid","@id":"https:\/\/brakkeconsulting.com\/pt\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"headline":"Brakke Viewpoint March 6, 2026","datePublished":"2026-03-06T16:10:33+00:00","mainEntityOfPage":{"@id":"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-march-6-2026\/"},"wordCount":249,"articleSection":["Viewpoints"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-march-6-2026\/","url":"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-march-6-2026\/","name":"Not\u00edcias da Brakke Consulting","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/pt\/#website"},"datePublished":"2026-03-06T16:10:33+00:00","author":{"@id":"https:\/\/brakkeconsulting.com\/pt\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"breadcrumb":{"@id":"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-march-6-2026\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-march-6-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-march-6-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/brakkeconsulting.com\/pt\/"},{"@type":"ListItem","position":2,"name":"Brakke Viewpoint March 6, 2026"}]},{"@type":"WebSite","@id":"https:\/\/brakkeconsulting.com\/pt\/#website","url":"https:\/\/brakkeconsulting.com\/pt\/","name":"Site da Brakke Consulting","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/brakkeconsulting.com\/pt\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Person","@id":"https:\/\/brakkeconsulting.com\/pt\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615","name":"Amanda McDavid","url":"https:\/\/brakkeconsulting.com\/pt\/author\/amanda\/"}]}},"_links":{"self":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/36285","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/comments?post=36285"}],"version-history":[{"count":1,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/36285\/revisions"}],"predecessor-version":[{"id":36286,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/36285\/revisions\/36286"}],"wp:attachment":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/media?parent=36285"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/categories?post=36285"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/tags?post=36285"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}